COMP <GO>
MDGL vs ABBV // RSI-14 & 200D SMA MOMENTUM
Madrigal Pharmaceuticals Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: MDGL 4
— ABBV 10
▲ RSI-14 & 200D SMA MOMENTUM LEADER: ABBV
LAST: $430.36 (-0.31%) • MKT CAP: $9.97B
rsi-technicals
29.5
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
rsi-technicals
72.8
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MDGL VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MDGL | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 70.20% | -29.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -29.70% | 29.00% | -58.70 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.91% | 3.47% | -5.38 | ABBV | /fcf-yield <GO> |
| Operating Margin | -31.30% | 24.60% | -55.90 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -30.10% | 6.90% | -37.00 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 8.60% | +171.40 | MDGL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.65 | 5.33 | +2.32 | MDGL | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 7.40% | -0.20 | MDGL | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 29.5 | 72.8 | -43.28 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 1.15 | -0.07 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 24.0x | 113.1x | -89.10 | MDGL | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.97B | $513.86B | -$503.89B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MDGL REV | ABBV REV | MDGL GROSS % | ABBV GROSS % | MDGL FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $958.4M | $61.16B | 44.0% | 70.2% | -$190.0M | $17.82B |
| FY 2024 | $180.1M | $56.33B | 96.5% | 70.0% | -$457.0M | $17.83B |
| FY 2023 | $0 | $54.32B | — | 44.0% | -$324.2M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MDGL // BETA 1.08
ABBV // BETA 1.15